- $10.32bn
- $9.20bn
- $2.17bn
- 98
- 46
- 100
- 95
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 17.48 | ||
| PEG Ratio (f) | 2.47 | ||
| EPS Growth (f) | 7.61% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.6 | ||
| Price to Tang. Book | 4.73 | ||
| Price to Free Cashflow | 15.36 | ||
| Price to Sales | 4.76 | ||
| EV to EBITDA | 14.53 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 23.77% | ||
| Return on Equity | 23.13% | ||
| Operating Margin | 27.88% | ||
Financial Summary
| Year End 3rd Jan | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 987.54 | 1,434.97 | 1,611.06 | 1,830.21 | 2,168.7 | 2,249 | 2,494.93 | 17.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -65.51 | +103.92 | -21.65 | +15.08 | +206.45 | +1.43 | +21.2 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.
Directors
- Stelios Papadopoulos NEC (72)
- Michael Morrissey CEO (60)
- Christopher Senner CFO (53)
- Peter Lamb EVP (60)
- Jeffrey Hessekiel EVP (52)
- Vicki Goodman EVP
- Patrick Haley EVP (45)
- Jacqueline Wright DRC
- Charles Cohen IND (70)
- Carl Feldbaum IND (77)
- Maria Freire IND (66)
- Alan Garber IND (65)
- Vincent Marchesi IND (85)
- George Poste IND (76)
- Julie Smith IND (50)
- Lance Willsey IND (59)
- Jack Wyszomierski IND (65)
- Last Annual
- January 3rd, 2025
- Last Interim
- January 3rd, 2025
- Incorporated
- November 15th, 1994
- Public Since
- April 11th, 2000
- No. of Shareholders
- 305
- No. of Employees
- 1,147
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 275,583,955
- Address
- 1851 Harbor Bay Parkway, ALAMEDA, 94502
- Web
- https://www.exelixis.com/
- Phone
- +1 6508377000
- Auditors
- Ernst & Young LLP
Upcoming Events for EXEL
Exelixis Inc Annual Shareholders Meeting
Q2 2025 Exelixis Inc Earnings Release
Q3 2025 Exelixis Inc Earnings Release
Similar to EXEL
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
What is the Exelixis share price?
As of Today at 20:33 UTC, shares in Exelixis are trading at $37.43. This share price information is delayed by 15 minutes.
How has the Exelixis share price performed this year?
Shares in Exelixis last closed at $37.43 and the price had moved by +59.07% over the past 365 days. In terms of relative price strength the Exelixis share price has outperformed the S&P500 Index by +46.83% over the past year.
What are the analyst and broker recommendations for Exelixis?
The overall consensus recommendation for Exelixis is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Exelixis dividend yield?
Exelixis does not currently pay a dividend.
Does Exelixis pay a dividend?
Exelixis does not currently pay a dividend.
When does Exelixis next pay dividends?
Exelixis does not currently pay a dividend.
How do I buy Exelixis shares?
To buy shares in Exelixis you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Exelixis?
As of the previous close price of $37.43, shares in Exelixis had a market capitalisation of $10.32bn.
Where are Exelixis shares listed?
Here are the trading details for Exelixis:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: EXEL
What kind of share is Exelixis?
Based on an overall assessment of its quality, value and momentum Exelixis is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Exelixis share price forecast for 2025?
The analyst consensus target price for shares in Exelixis is $37.95. That is 1.39% above the last closing price of $37.43.
Analysts covering Exelixis currently have a consensus Earnings Per Share (EPS) forecast of $2.01 for the next financial year.
Find out moreWhat is the trend in the Exelixis share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Exelixis. Over the past six months, its share price has outperformed the S&P500 Index by +41.55%.
As of the last closing price of $37.43, shares in Exelixis were trading +18.47% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Exelixis PE Ratio?
The Exelixis PE ratio based on its reported earnings over the past 12 months is 17.48. The shares last closed at $37.43.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Exelixis?
Exelixis' management team is headed by:
- Stelios Papadopoulos - NEC
- Michael Morrissey - CEO
- Christopher Senner - CFO
- Peter Lamb - EVP
- Jeffrey Hessekiel - EVP
- Vicki Goodman - EVP
- Patrick Haley - EVP
- Jacqueline Wright - DRC
- Charles Cohen - IND
- Carl Feldbaum - IND
- Maria Freire - IND
- Alan Garber - IND
- Vincent Marchesi - IND
- George Poste - IND
- Julie Smith - IND
- Lance Willsey - IND
- Jack Wyszomierski - IND